Evolus Announces Publication Of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau
Portfolio Pulse from Benzinga Newsdesk
Evolus, Inc. (NASDAQ:EOLS) announced the publication of Phase 2 study results in the Aesthetic Surgery Journal, demonstrating the safety and 6-month duration of effect of its 'extra-strength' 40U Jeuveau formulation for treating moderate to severe glabellar lines. The study, which compared Jeuveau 40U against two active controls (BOTOX 20U and Jeuveau 20U), showed a similar safety profile across all groups, with the majority of adverse events being mild and no serious adverse events reported. This data was presented at the 2023 ASDS Annual Meeting.
April 17, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evolus, Inc. announced positive Phase 2 results for its 'extra-strength' 40U Jeuveau formulation, showing safety and a 6-month duration of effect for treating glabellar lines, with no serious adverse events.
The publication of positive Phase 2 study results typically has a favorable impact on a company's stock price, especially when it involves a flagship product like Jeuveau. The confirmation of safety and efficacy over a 6-month period, without serious adverse events, enhances the product's marketability and could lead to increased sales and market share in the competitive aesthetic medicine sector. Given the direct involvement of Evolus in this study and the potential for increased revenue from Jeuveau, the news is highly relevant and important to investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100